Teva Pharmaceutical Industries Ltd. plunged to the lowest in more than a decade following a U.S. court ruling that invalidated four patents on its best-selling multiple sclerosis drug Copaxone. The ruling, issued late on Monday, may open the door to generic competition for a drug that generates a fifth of Teva’s $20 billion in annual sales.